<p><em><strong>一月會議將重點介紹 Zomedica 不斷擴展的數字能力和長期創新戰略</strong></em></p>
<p>Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;）是一家為馬匹和伴侶動物提供創新診斷和治療設備的動物健康公司，今天宣佈其&#34;每月第四個星期五四點&#34;投資者網絡研討會系列的下一期，定於 <strong>2026 年 1 月 23 日星期五東部時間下午 4:00</strong> 舉行。</p>
<p>一月的主題為 <strong>&#34;數字優勢：通過創新推動可擴展增長&#34;</strong>，將為投資者提供深入瞭解 Zomedica 如何構建數字體驗和部署數字技術以創造產品創新，從而推動可持續收入擴展、運營槓桿和長期股東價值的機會。討論將重點介紹公司的數字生態系統、技術驅動的產品管道以及旨在增強 Zomedica 在獸醫診斷和治療領域競爭地位的戰略舉措。</p>
<p>&#34;Zomedica 的數字戰略並不是孤立的技術舉措——而是構建連接的智能平台，以推動更好的臨牀結果，加速產品採用，並創造可擴展、可重複的增長，&#34;Zomedica 創新技術副總裁 <strong>Evan St. Peter</strong> 表示。&#34;隨着我們繼續在診斷、治療和數據驅動解決方案方面進行創新投資，我們正在為客户和股東創造長期價值奠定基礎。&#34;</p>
<p>投資者和相關利益相關者可以在此註冊： https://sholink.to/January2026</p>
<p><strong>網絡研討會詳情</strong></p>
<p><strong>標題：</strong> <em>每月第四個星期五四點 - 數字優勢：通過創新推動可擴展增長</em></p>
<p>** 日期/時間：**2026 年 1 月 23 日星期五，東部時間下午 4:00</p>
<p><strong>註冊：</strong> https://sholink.to/January2026</p>
<p><strong>形式：</strong> 準備好的發言後進行問答環節</p>
<p><strong>關於 Zomedica</strong></p>
<p>Zomedica 是一家領先的馬匹和伴侶動物健康公司，致力於通過為獸醫提供創新的治療和診斷解決方案來改善動物健康。我們的金標準 PulseVet®衝擊波系統加速了肌肉骨骼疾病的癒合，改變了獸醫治療。我們的產品系列還包括 Assisi®治療設備系列、TRUFORMA®診斷平台、TRUVIEW®數字細胞學系統、VetGuardian®零接觸監測系統和 VETIGEL®止血凝膠，這是一種革命性的止血劑，能夠迅速止血，所有這些都旨在賦能獸醫提供頂級護理。在美國，它們的總可尋址市場超過 20 億美元。Zomedica 總部位於密歇根州，僱傭約 150 名員工，並在喬治亞州和明尼蘇達州的世界級設施中製造和分銷其產品。Zomedica 在 2024 年實現了 8% 的收入增長，達到 2700 萬美元，並在 2025 年 9 月 30 日時保持約 5440 萬美元的流動資金，資產負債表強勁。Zomedica 正在推進其產品供應，利用戰略收購，並在國際上擴展，以提升寵物護理質量，增加寵物家長的滿意度，並改善獸醫實踐的工作流程、現金流和盈利能力。有關更多信息，請訪問 www.zomedica.com。</p>
<p><strong>關注 Zomedica</strong></p>
<ul>
<li>郵件提醒： http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X（前 Twitter）： https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>除歷史事實的陳述外，本新聞稿包含某些&#34;前瞻性信息&#34;或&#34;前瞻性聲明&#34;（統稱&#34;前瞻性信息&#34;），符合適用證券法的定義。前瞻性信息通常以&#34;計劃&#34;、&#34;期望&#34;、&#34;預測&#34;、&#34;打算&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;估計&#34;及其他類似詞彙或某些事件或條件&#34;可能&#34;或&#34;將&#34;發生的聲明來表述，幷包括與我們對未來結果的預期相關的聲明。儘管我們相信前瞻性信息中反映的預期是合理的，但不能保證這些預期會被證明是正確的。我們無法保證未來的結果、表現或成就。因此，不能保證實際結果與前瞻性信息中列出的結果在整體或部分上相同。</p>
<p>前瞻性信息基於管理層在聲明發布時的意見和估計，包括對經濟增長、公司產品需求、公司生產和銷售產品能力、預算資本和運營支出的充足性、戰略合作伙伴在商業協議下履行義務的滿意度以及我們實現商業計劃和成本控制努力的能力的假設。</p>
<p>我們的前瞻性信息受到多種風險和不確定性以及其他因素的影響，這些因素可能導致實際事件或結果與前瞻性信息中預期的結果存在重大差異。一些可能導致結果與前瞻性信息中表達的內容存在重大差異的風險和其他因素包括但不限於：臨牀研究的結果、普遍接受的會計原則的應用，這些原則高度複雜，涉及許多主觀假設、估計和判斷；我們戰略和商業計劃是否能帶來預期收益的不確定性；開發工作及驗證和確認研究的時間和結果的不確定性；商業化努力的時間和結果的不確定性，包括國際努力，以及商業化努力的成本，包括開發內部銷售團隊和管理我們增長的成本；我們能否實現收購所帶來的預期增長機會的不確定性；我們能否根據客户需求供應產品的不確定性；與關税變化相關的供應鏈風險；任何所需監管批准的可能性和時間的不確定性，以及資本的可用性和成本；識別、開發和實現新產品和技術商業成功的能力；在採用我們的資本設備後，獸醫對我們產品的接受度和對耗材的購買；來自相關產品的競爭；維持和提高產品和服務質量所需支出的水平；技術變化和法律法規的變化；我們確保和維持戰略關係的能力；我們的戰略合作伙伴在商業協議下履行其義務的表現，包括產品製造義務；與許可證和許可相關的風險、知識產權侵權風險、與任何所需臨牀試驗和監管批准相關的風險、與我們產品的安全性和有效性、產品使用、知識產權保護以及在我們向 SEC 提交的文件和在 www.sedarplus.com 上的資料中披露的其他風險因素相關的風險。讀者應注意，這份風險因素清單不應被解釋為詳盡無遺。</p>
<p>本新聞稿中包含的前瞻性信息明確受到本警示聲明的限制。除非適用的證券立法另有要求，否則我們不承擔更新任何前瞻性信息以使其與實際結果或我們的預期變化相符的義務。讀者應謹慎對待前瞻性信息，避免過度依賴。</p>
<p><strong>投資者關係聯繫人：</strong></p>
<p>Zomedica 投資者關係</p>
<p><strong>Investors@zomedica.com</strong></p>
<p>1-734-369-2555</p>
<p><strong>來源：</strong> Zomedica Corp.</p>
<p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ"/></p>

ZOMDF

<p>Zomedica Corp.（OTCQB:ZOMDF）將於 2026 年 1 月 23 日舉辦其 “第四個星期五四點鐘” 投資者網絡研討會，重點討論數字創新和技術驅動的增長。此次會議的主題為 “數字優勢：通過創新推動可擴展增長”，將展示 Zomedica 的數字能力和長期創新戰略，旨在提升獸醫診斷和治療。公司報告稱，2024 年收入增長 8%，達到 2700 萬美元，並在 2025 年 9 月 30 日保持約 5440 萬美元的強勁流動性。感興趣的利益相關者可以註冊參加該網絡研討會</p>

<p><em><strong>January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy</strong></em></p>
<div class="lb-trans"><p><em><strong>一月會議將重點介紹 Zomedica 不斷擴展的數字能力和長期創新戰略</strong></em></p>
</div><p>Zomedica Corp. (OTCQB:ZOMDF) (&#34;Zomedica&#34; or the &#34;Company&#34;), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced the next installment of its &#34;Fourth Friday at Four&#34; investor webinar series, scheduled for <strong>Friday, January 23, 2026 at 4:00 p.m. Eastern Time</strong>.</p>
<div class="lb-trans"><p>Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;）是一家為馬匹和伴侶動物提供創新診斷和治療設備的動物健康公司，今天宣佈其&#34;每月第四個星期五四點&#34;投資者網絡研討會系列的下一期，定於 <strong>2026 年 1 月 23 日星期五東部時間下午 4:00</strong> 舉行。</p>
</div><p>The January program, titled <strong>&#34;Digital Advantage: Powering Scalable Growth Through Innovation,&#34;</strong> will provide investors with an in-depth look at how Zomedica is building digital experiences and deploying digital technology to create product innovation to drive sustainable revenue expansion, operating leverage, and long-term shareholder value. The discussion will highlight the Company's evolving digital ecosystem, technology-enabled product pipeline, and strategic initiatives designed to strengthen Zomedica's competitive position across veterinary diagnostics and therapeutics.</p>
<div class="lb-trans"><p>一月的主題為 <strong>&#34;數字優勢：通過創新推動可擴展增長&#34;</strong>，將為投資者提供深入瞭解 Zomedica 如何構建數字體驗和部署數字技術以創造產品創新，從而推動可持續收入擴展、運營槓桿和長期股東價值的機會。討論將重點介紹公司的數字生態系統、技術驅動的產品管道以及旨在增強 Zomedica 在獸醫診斷和治療領域競爭地位的戰略舉措。</p>
</div><p>&#34;Zomedica's digital strategy is not about isolated technology initiatives - it is about building connected, intelligent platforms that drive better clinical outcomes, accelerate product adoption, and create scalable, repeatable growth,&#34; said <strong>Evan St. Peter, Vice President of Innovation Technology at Zomedica</strong>. &#34;As we continue to invest in innovation across diagnostics, therapeutics, and data-driven solutions, we are creating a foundation for long-term value creation for both customers and shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;Zomedica 的數字戰略並不是孤立的技術舉措——而是構建連接的智能平台，以推動更好的臨牀結果，加速產品採用，並創造可擴展、可重複的增長，&#34;Zomedica 創新技術副總裁 <strong>Evan St. Peter</strong> 表示。&#34;隨着我們繼續在診斷、治療和數據驅動解決方案方面進行創新投資，我們正在為客户和股東創造長期價值奠定基礎。&#34;</p>
</div><p>Investors and interested stakeholders can register here: https://sholink.to/January2026</p>
<div class="lb-trans"><p>投資者和相關利益相關者可以在此註冊： https://sholink.to/January2026</p>
</div><p><strong>Webinar Details</strong></p>
<div class="lb-trans"><p><strong>網絡研討會詳情</strong></p>
</div><p><strong>Title:</strong> <em>Fourth Friday at Four - Digital Advantage: Powering Scalable Growth Through Innovation</em></p>
<div class="lb-trans"><p><strong>標題：</strong> <em>每月第四個星期五四點 - 數字優勢：通過創新推動可擴展增長</em></p>
</div><p><strong>Date/Time:</strong> Friday, January 23, 2026, at 4:00 p.m. Eastern Time</p>
<div class="lb-trans"><p>** 日期/時間：**2026 年 1 月 23 日星期五，東部時間下午 4:00</p>
</div><p><strong>Registration:</strong> https://sholink.to/January2026</p>
<div class="lb-trans"><p><strong>註冊：</strong> https://sholink.to/January2026</p>
</div><p><strong>Format:</strong> Prepared remarks followed by Question &amp; Answer session</p>
<div class="lb-trans"><p><strong>形式：</strong> 準備好的發言後進行問答環節</p>
</div><p><strong>About Zomedica</strong></p>
<div class="lb-trans"><p><strong>關於 Zomedica</strong></p>
</div><p>Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian® Zero Touch™ monitoring system, and VETIGEL® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, all designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as it works to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.</p>
<div class="lb-trans"><p>Zomedica 是一家領先的馬匹和伴侶動物健康公司，致力於通過為獸醫提供創新的治療和診斷解決方案來改善動物健康。我們的金標準 PulseVet®衝擊波系統加速了肌肉骨骼疾病的癒合，改變了獸醫治療。我們的產品系列還包括 Assisi®治療設備系列、TRUFORMA®診斷平台、TRUVIEW®數字細胞學系統、VetGuardian®零接觸監測系統和 VETIGEL®止血凝膠，這是一種革命性的止血劑，能夠迅速止血，所有這些都旨在賦能獸醫提供頂級護理。在美國，它們的總可尋址市場超過 20 億美元。Zomedica 總部位於密歇根州，僱傭約 150 名員工，並在喬治亞州和明尼蘇達州的世界級設施中製造和分銷其產品。Zomedica 在 2024 年實現了 8% 的收入增長，達到 2700 萬美元，並在 2025 年 9 月 30 日時保持約 5440 萬美元的流動資金，資產負債表強勁。Zomedica 正在推進其產品供應，利用戰略收購，並在國際上擴展，以提升寵物護理質量，增加寵物家長的滿意度，並改善獸醫實踐的工作流程、現金流和盈利能力。有關更多信息，請訪問 www.zomedica.com。</p>
</div><p><strong>Follow Zomedica</strong></p>
<div class="lb-trans"><p><strong>關注 Zomedica</strong></p>
</div><ul>
<li>Email Alerts: http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X (formerly Twitter): https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<div class="lb-trans"><ul>
<li>郵件提醒： http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X（前 Twitter）： https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>Except for statements of historical fact, this news release contains certain &#34;forward-looking information&#34; or &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as &#34;plan&#34;, &#34;expect&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;estimate&#34; and other similar words, or statements that certain events or conditions &#34;may&#34; or &#34;will&#34; occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.</p>
<div class="lb-trans"><p>除歷史事實的陳述外，本新聞稿包含某些&#34;前瞻性信息&#34;或&#34;前瞻性聲明&#34;（統稱&#34;前瞻性信息&#34;），符合適用證券法的定義。前瞻性信息通常以&#34;計劃&#34;、&#34;期望&#34;、&#34;預測&#34;、&#34;打算&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;估計&#34;及其他類似詞彙或某些事件或條件&#34;可能&#34;或&#34;將&#34;發生的聲明來表述，幷包括與我們對未來結果的預期相關的聲明。儘管我們相信前瞻性信息中反映的預期是合理的，但不能保證這些預期會被證明是正確的。我們無法保證未來的結果、表現或成就。因此，不能保證實際結果與前瞻性信息中列出的結果在整體或部分上相同。</p>
</div><p>Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.</p>
<div class="lb-trans"><p>前瞻性信息基於管理層在聲明發布時的意見和估計，包括對經濟增長、公司產品需求、公司生產和銷售產品能力、預算資本和運營支出的充足性、戰略合作伙伴在商業協議下履行義務的滿意度以及我們實現商業計劃和成本控制努力的能力的假設。</p>
</div><p>Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.</p>
<div class="lb-trans"><p>我們的前瞻性信息受到多種風險和不確定性以及其他因素的影響，這些因素可能導致實際事件或結果與前瞻性信息中預期的結果存在重大差異。一些可能導致結果與前瞻性信息中表達的內容存在重大差異的風險和其他因素包括但不限於：臨牀研究的結果、普遍接受的會計原則的應用，這些原則高度複雜，涉及許多主觀假設、估計和判斷；我們戰略和商業計劃是否能帶來預期收益的不確定性；開發工作及驗證和確認研究的時間和結果的不確定性；商業化努力的時間和結果的不確定性，包括國際努力，以及商業化努力的成本，包括開發內部銷售團隊和管理我們增長的成本；我們能否實現收購所帶來的預期增長機會的不確定性；我們能否根據客户需求供應產品的不確定性；與關税變化相關的供應鏈風險；任何所需監管批准的可能性和時間的不確定性，以及資本的可用性和成本；識別、開發和實現新產品和技術商業成功的能力；在採用我們的資本設備後，獸醫對我們產品的接受度和對耗材的購買；來自相關產品的競爭；維持和提高產品和服務質量所需支出的水平；技術變化和法律法規的變化；我們確保和維持戰略關係的能力；我們的戰略合作伙伴在商業協議下履行其義務的表現，包括產品製造義務；與許可證和許可相關的風險、知識產權侵權風險、與任何所需臨牀試驗和監管批准相關的風險、與我們產品的安全性和有效性、產品使用、知識產權保護以及在我們向 SEC 提交的文件和在 www.sedarplus.com 上的資料中披露的其他風險因素相關的風險。讀者應注意，這份風險因素清單不應被解釋為詳盡無遺。</p>
</div><p>The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.</p>
<div class="lb-trans"><p>本新聞稿中包含的前瞻性信息明確受到本警示聲明的限制。除非適用的證券立法另有要求，否則我們不承擔更新任何前瞻性信息以使其與實際結果或我們的預期變化相符的義務。讀者應謹慎對待前瞻性信息，避免過度依賴。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者關係聯繫人：</strong></p>
</div><p>Zomedica Investor Relations</p>
<div class="lb-trans"><p>Zomedica 投資者關係</p>
</div><p><strong>Investors@zomedica.com</strong></p>
<div class="lb-trans"><p><strong>Investors@zomedica.com</strong></p>
</div><p>1-734-369-2555</p>
<div class="lb-trans"><p>1-734-369-2555</p>
</div><p><strong>SOURCE:</strong> Zomedica Corp.</p>
<div class="lb-trans"><p><strong>來源：</strong> Zomedica Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1126935"/></p>

Zomedica 宣佈將於 1 月 23 日舉辦 “第四個星期五下午四點” 網絡研討會，重點討論數字創新和技術驅動的增長 | ZOMDF 股票新聞